These studies also indicate that pembrolizumab treatment has manageable side effects, and prior monitoring of the NSCLC patients for PD-L1 expression can be a judicious approach in deciding the use of the PD1/PD-L1 blocking antibody. Here, PDCD1 is linked to non-small cell lung carcinoma.